Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company, has scheduled the release of its first quarter 2025 financial results for Monday, May 19, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 AM ET where management will discuss the results and provide a corporate update. Investors can join via phone (U.S.: 1-866-744-5399, International: +972-3-918-0644) or through the company's website. A replay will be available on their website after the live event.
Compugen Ltd. (NASDAQ: CGEN), un'azienda in fase clinica specializzata in immunoterapia oncologica, ha programmato la pubblicazione dei suoi risultati finanziari del primo trimestre 2025 per lunedì 19 maggio 2025, prima dell'apertura dei mercati statunitensi. La società terrà una conference call e una webcast alle 8:30 AM ET durante le quali la direzione discuterà i risultati e fornirà un aggiornamento aziendale. Gli investitori potranno partecipare telefonicamente (USA: 1-866-744-5399, Internazionale: +972-3-918-0644) o tramite il sito web dell'azienda. Una registrazione sarà disponibile sul sito dopo l'evento in diretta.
Compugen Ltd. (NASDAQ: CGEN), una compañía en etapa clínica dedicada a la inmunoterapia contra el cáncer, ha programado la publicación de sus resultados financieros del primer trimestre de 2025 para el lunes 19 de mayo de 2025, antes de la apertura de los mercados en EE. UU. La empresa realizará una llamada conferencia y una transmisión en vivo a las 8:30 AM ET, donde la dirección discutirá los resultados y ofrecerá una actualización corporativa. Los inversores podrán unirse por teléfono (EE. UU.: 1-866-744-5399, Internacional: +972-3-918-0644) o a través del sitio web de la compañía. Una repetición estará disponible en su sitio web tras el evento en vivo.
컴퓨젠 Ltd. (NASDAQ: CGEN)은 임상 단계의 암 면역치료 회사로, 2025년 1분기 재무 결과를 2025년 5월 19일 월요일 미국 시장 개장 전 발표할 예정입니다. 회사는 동부시간 기준 오전 8시 30분에 컨퍼런스 콜과 웹캐스트를 진행하며 경영진이 결과를 논의하고 회사 현황을 업데이트할 예정입니다. 투자자들은 전화(미국: 1-866-744-5399, 국제: +972-3-918-0644) 또는 회사 웹사이트를 통해 참여할 수 있습니다. 생중계 후 웹사이트에서 다시보기 서비스를 제공할 예정입니다.
Compugen Ltd. (NASDAQ : CGEN), une société en phase clinique spécialisée dans l'immunothérapie du cancer, a prévu la publication de ses résultats financiers du premier trimestre 2025 pour le lundi 19 mai 2025, avant l'ouverture des marchés américains. La société organisera une conférence téléphonique et une webcast à 8h30 ET où la direction discutera des résultats et fournira une mise à jour de l'entreprise. Les investisseurs pourront participer par téléphone (États-Unis : 1-866-744-5399, International : +972-3-918-0644) ou via le site web de la société. Une rediffusion sera disponible sur leur site après l'événement en direct.
Compugen Ltd. (NASDAQ: CGEN), ein klinisch fortgeschrittenes Unternehmen für Krebsimmuntherapie, hat die Veröffentlichung seiner Finanzergebnisse für das erste Quartal 2025 für Montag, den 19. Mai 2025 vor Öffnung der US-Märkte geplant. Das Unternehmen wird eine Telefonkonferenz und eine Webcast um 8:30 Uhr ET abhalten, bei der das Management die Ergebnisse besprechen und ein Unternehmensupdate geben wird. Investoren können telefonisch (USA: 1-866-744-5399, International: +972-3-918-0644) oder über die Webseite des Unternehmens teilnehmen. Eine Aufzeichnung wird nach der Live-Veranstaltung auf der Webseite verfügbar sein.
- None.
- None.
HOLON,
To access the live conference call by telephone, please dial 1-866-744-5399 from the
or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the following link. Following the live webcast, a replay will be available on the Company's website.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-release-first-quarter-2025-results-on-monday-may-19-2025-302445841.html
SOURCE Compugen Ltd.
FAQ
When will Compugen (CGEN) release Q1 2025 earnings?
What time is Compugen's Q1 2025 earnings call?
How can I join Compugen's Q1 2025 earnings call?
Will there be a replay of Compugen's Q1 2025 earnings call?
